• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 SEER 数据库和科室队列分析的肝上皮样血管内皮细胞瘤亚组临床结局的综合评估。

Comprehensive evaluation of clinical outcomes in hepatic epithelioid hemangioendothelioma subsets: insights from SEER Database and departmental cohort analysis.

机构信息

Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Immunol. 2024 Oct 22;15:1491922. doi: 10.3389/fimmu.2024.1491922. eCollection 2024.

DOI:10.3389/fimmu.2024.1491922
PMID:39502705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534872/
Abstract

BACKGROUND

Epithelioid hemangioendothelioma (EHE), is an uncommon, intermediate-grade malignant vascular tumor that can manifest in diverse organs, including the liver, lungs, and bones. Given its unique malignancy profile and rarity, there lacks a consensus on a standardized treatment protocol for EHE, particularly for hepatic epithelioid hemangioendothelioma (HEHE). This study aims to elucidate factors influencing the clinical prognosis of EHE by analyzing data from the SEER database, complemented with insights from a departmental cohort of 9 HEHE cases. Through this, we hope to shed light on potential clinical outcomes and therapeutic strategies for HEHE.

METHODS

Using SEER data from 22 registries, we analyzed 313 liver cancer patients with ICD-O-3 9130 and 9133 histology. Twelve variables were examined using Cox regression and mlr3 machine learning. Significant variables were identified and compared. Clinical data, imaging characteristics, and treatment methods of nine patients from our cohort were also presented.

RESULT

In univariate and multivariate Cox regression analyses, Age, Sex, Year of diagnosis, Surgery of primary site, Chemotherapy, and Median household income were closely related to survival outcomes. Among the ten survival-related machine learning models, CoxPH, Flexible, Mboost, and Gamboost stood out based on Area Under the Curve(AUC), Decision Curve Analysis(DCA), and Calibration Curve Metrics. In the feature importance analysis of these four selected models, Age and Surgery of primary site were consistently identified as the most critical factors influencing prognosis. Additionally, the clinical data of nine patients from our cohort not only demonstrated unique imaging characteristics of HEHE but also underscored the importance of surgical intervention.

CONCLUSION

For patients with resectable HEHE, surgical treatment is currently a highly important therapeutic approach.

摘要

背景

上皮样血管内皮细胞瘤(EHE)是一种罕见的、中等恶性的血管肿瘤,可发生于多种器官,包括肝脏、肺部和骨骼。由于其独特的恶性特征和罕见性,对于 EHE 缺乏标准化的治疗方案共识,特别是对于肝脏上皮样血管内皮细胞瘤(HEHE)。本研究旨在通过分析 SEER 数据库中的数据,并结合 9 例 HEHE 病例的科室队列,阐明影响 EHE 临床预后的因素。通过这种方式,我们希望为 HEHE 的潜在临床结果和治疗策略提供一些启示。

方法

我们使用来自 22 个登记处的 SEER 数据,分析了 313 例具有 ICD-O-3 9130 和 9133 组织学的肝癌患者。使用 Cox 回归和 mlr3 机器学习分析了 12 个变量。识别并比较了显著变量。还介绍了我们队列中 9 名患者的临床数据、影像学特征和治疗方法。

结果

在单变量和多变量 Cox 回归分析中,年龄、性别、诊断年份、原发部位手术、化疗和家庭中位数收入与生存结果密切相关。在十个与生存相关的机器学习模型中,CoxPH、Flexible、Mboost 和 Gamboost 在曲线下面积(AUC)、决策曲线分析(DCA)和校准曲线指标方面表现突出。在这四个选定模型的特征重要性分析中,年龄和原发部位手术被一致认为是影响预后的最关键因素。此外,我们队列中 9 名患者的临床数据不仅显示了 HEHE 的独特影像学特征,还强调了手术干预的重要性。

结论

对于可切除的 HEHE 患者,手术治疗目前是一种非常重要的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/47386ebdc49f/fimmu-15-1491922-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/a1f938b50c7b/fimmu-15-1491922-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/81b6d3fb0309/fimmu-15-1491922-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/e43eedbc27fa/fimmu-15-1491922-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/d319738f1378/fimmu-15-1491922-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/3d8f5e114ade/fimmu-15-1491922-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/4afcc44a67ae/fimmu-15-1491922-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/47386ebdc49f/fimmu-15-1491922-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/a1f938b50c7b/fimmu-15-1491922-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/81b6d3fb0309/fimmu-15-1491922-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/e43eedbc27fa/fimmu-15-1491922-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/d319738f1378/fimmu-15-1491922-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/3d8f5e114ade/fimmu-15-1491922-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/4afcc44a67ae/fimmu-15-1491922-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d71/11534872/47386ebdc49f/fimmu-15-1491922-g007.jpg

相似文献

1
Comprehensive evaluation of clinical outcomes in hepatic epithelioid hemangioendothelioma subsets: insights from SEER Database and departmental cohort analysis.基于 SEER 数据库和科室队列分析的肝上皮样血管内皮细胞瘤亚组临床结局的综合评估。
Front Immunol. 2024 Oct 22;15:1491922. doi: 10.3389/fimmu.2024.1491922. eCollection 2024.
2
Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2014.基于 1973 年至 2014 年 SEER 数据分析的肝上皮样血管内皮细胞瘤的治疗和预后。
Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):29-35. doi: 10.1016/j.hbpd.2019.11.006. Epub 2019 Nov 29.
3
Tumor Biology Impacts Survival in Surgically Managed Primary Hepatic Vascular Malignancies.肿瘤生物学影响原发性肝血管恶性肿瘤手术治疗的生存。
J Surg Res. 2021 Aug;264:481-489. doi: 10.1016/j.jss.2021.02.043. Epub 2021 Apr 12.
4
Imaging characteristics and prognostic values of hepatic epithelioid hemangioendothelioma on F-FDG PET/CT.F-FDG PET/CT 下肝脏上皮样血管内皮细胞瘤的影像学特征及预后价值。
Clin Exp Med. 2020 Nov;20(4):557-567. doi: 10.1007/s10238-020-00653-0. Epub 2020 Aug 14.
5
Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma Is Facilitated by Exception Points With Acceptable Long-term Outcomes.肝上皮样血管内皮细胞瘤的肝移植:通过例外积分制可获得可接受的长期疗效。
Transplantation. 2020 Jun;104(6):1187-1192. doi: 10.1097/TP.0000000000002982.
6
Long-term prognosis and treatment modalities of hepatic epithelioid hemangioendothelioma: a retrospective study of 228 patients.肝上皮样血管内皮细胞瘤的长期预后和治疗方式:228 例回顾性研究。
BMC Cancer. 2024 Oct 16;24(1):1285. doi: 10.1186/s12885-024-13053-4.
7
Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry.肝上皮样血管内皮瘤与成人肝移植:基于ELTR-ELITA注册研究分析的预后评分建议
Transplantation. 2017 Mar;101(3):555-564. doi: 10.1097/TP.0000000000001603.
8
Hepatic Epithelioid Hemangioendothelioma: A Rare Disease With Favorable Outcomes After Liver Transplantation.肝上皮样血管内皮瘤:一种肝移植后预后良好的罕见疾病。
Transplant Proc. 2020 Oct;52(8):2447-2449. doi: 10.1016/j.transproceed.2020.02.101. Epub 2020 Mar 23.
9
Pathological characteristics of liver biopsies in eight patients with hepatic epithelioid hemangioendothelioma.8例肝上皮样血管内皮瘤患者肝脏活检的病理特征
Int J Clin Exp Pathol. 2015 Sep 1;8(9):11015-23. eCollection 2015.
10
Selection of treatment for hepatic epithelioid hemangioendothelioma: a single-center experience.肝上皮样血管内皮细胞瘤治疗的选择:单中心经验。
World J Surg Oncol. 2019 Nov 7;17(1):183. doi: 10.1186/s12957-019-1729-y.

本文引用的文献

1
Loss of CDKN2A Cooperates with WWTR1(TAZ)-CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma.CDKN2A 缺失与 WWTR1(TAZ)-CAMTA1 基因融合协同促进上皮样血管内皮细胞瘤的肿瘤进展。
Clin Cancer Res. 2023 Jul 5;29(13):2480-2493. doi: 10.1158/1078-0432.CCR-22-2497.
2
A review of hepatic epithelioid hemangioendothelioma-Analyzing patient characteristics and treatment strategies.肝上皮样血管内皮细胞瘤的综述——分析患者特征和治疗策略。
J Surg Oncol. 2022 Dec;126(8):1423-1429. doi: 10.1002/jso.27066. Epub 2022 Aug 17.
3
The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma.
TAZ-CAMTA1 融合蛋白通过结缔组织生长因子和 Ras-MAPK 信号通路促进上皮样血管内皮细胞瘤的肿瘤发生。
Clin Cancer Res. 2022 Jul 15;28(14):3116-3126. doi: 10.1158/1078-0432.CCR-22-0421.
4
MRI appearances of hepatic epithelioid hemangioendothelioma: a retrospective study of 57 patients.肝脏上皮样血管内皮瘤的MRI表现:57例患者的回顾性研究
Insights Imaging. 2022 Apr 5;13(1):65. doi: 10.1186/s13244-022-01213-8.
5
Efficacy and Safety of Interferon-Alpha 2b for Patients with Hepatic Epithelioid Hemangioendothelioma: Outcomes of a Case-Series Analysis.α-2b干扰素治疗肝上皮样血管内皮瘤患者的疗效与安全性:病例系列分析结果
Cancer Manag Res. 2021 Nov 3;13:8273-8279. doi: 10.2147/CMAR.S334171. eCollection 2021.
6
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.上皮样血管内皮细胞瘤,一种超罕见的癌症:来自专家社区的共识文件。
ESMO Open. 2021 Jun;6(3):100170. doi: 10.1016/j.esmoop.2021.100170. Epub 2021 Jun 2.
7
Treatment and Prognosis of Hepatic Epithelioid Hemangioendothelioma: A SEER Database Analysis.肝上皮样血管内皮细胞瘤的治疗与预后:SEER 数据库分析。
World J Surg. 2021 Sep;45(9):2886-2894. doi: 10.1007/s00268-021-06165-6. Epub 2021 May 17.
8
TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex.TAZ-CAMTA1 和 YAP-TFE3 通过募集 ATAC 组蛋白乙酰转移酶复合物来改变 TAZ/YAP 转录组。
Elife. 2021 Apr 29;10:e62857. doi: 10.7554/eLife.62857.
9
WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma.WWTR1(TAZ)-CAMTA1 重编程内皮细胞以驱动上皮样血管内皮细胞瘤。
Genes Dev. 2021 Apr 1;35(7-8):495-511. doi: 10.1101/gad.348221.120. Epub 2021 Mar 25.
10
(TAZ)- gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis.(TAZ)-基因融合足以使 YAP/TAZ 信号失调,并驱动上皮样血管内皮细胞瘤的肿瘤发生。
Genes Dev. 2021 Apr 1;35(7-8):512-527. doi: 10.1101/gad.348220.120. Epub 2021 Mar 25.